Qma cartridge

Manufactured by Waters Corporation

Sourced in Brazil, Germany, Japan

The QMA cartridge is a solid-phase extraction (SPE) device used for sample preparation in analytical chemistry. It is designed to selectively retain and concentrate analytes of interest from complex matrices prior to instrumental analysis. The QMA cartridge utilizes a quaternary methylamine sorbent for the purification and enrichment of anionic species. Its core function is to facilitate the efficient extraction and cleanup of these anionic compounds from various sample types.

Automatically generated - may contain errors

Lab products found in correlation

Pettrace cyclotron, by GE Healthcare (2 mentions) R d evo 3, by Elysia raytest (2 mentions) Sep pak c18 light cartridge, by Waters Corporation (1 mentions) 1200 series, by Agilent Technologies (1 mentions) Seppak light c18 cartridge, by Waters Corporation (1 mentions)

Spelling variants of this product

Sep-Pak QMA cartridge (6 citations) Sep-Pak Accell Plus QMA Plus Light Cartridge (5 citations) Sep-Pak Accell Plus QMA Carbonate Plus Light Cartridge (4 citations) Sep-Pak® light (46 mg) Accell™ plus QMA carbonate cartridges (3 citations) QMA light ion-exchange cartridges (2 citations) Sep-Pak QMA anion-exchange cartridges (2 citations) QMA Solid Phase Extraction (SPE) cartridges (2 citations) Sep-Pak QMA Carbonate Plus Light cartridges (2 citations) Sep-Pak Accell Plus QMA cartridge (2 citations) QMA SepPak Light anion exchange cartridge (2 citations)

8 protocols using qma cartridge

Radiosynthesis of [18F]Flurpiridaz

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 1

[¹⁸F]-fluoride (ca. 100 GBq) was produced using a GE Medical Systems PETtrace cyclotron with a silver target via the [¹⁸O](p,n) [¹⁸F] nuclear reaction. Total target volumes of 3.2-4.8 mL were used. The radiofluoride was trapped on a Waters QMA cartridge (pre-conditioned with carbonate), and the fluoride was eluted with a solution of tetrabutylammnonium hydrogen carbonate (22 mg) in water (100 μL) and acetonitrile (400 μL). Nitrogen was used to drive the solution off the QMA cartridge to the reaction vessel. The [¹⁸F]fluoride was dried for 9 minutes at 120° C. under a steady stream of nitrogen and vacuum. The precursor (10.2 mg, synthesized according to known methods) in MeCN (1.7 mL) was added to the dried [¹⁸F]-fluoride and the reaction mixture was heated at 120° C. for 10 minutes. The crude product was diluted with water (9.3 mL) and analysed by HPLC.

The % of [¹⁸F]Flurpiridaz in the crude product was 81% with 13% of a late eluting radiolysis product (FIG. 1). In once instance of the radiosynthesis the inventors observed only 72% [¹⁸F]Flurpiridaz.

US11565257B2. Stabilized radiolabelling reaction (2023-01-31). GE Healthcare Limited [GB]. Inventors: Torgrim Engell [NO], Alexander Jackson [GB], Imtiaz Ahmed Khan [GB], Alan Peter Clarke [NO], Graeme McRobbie [GB], Julian Grigg [GB].

+ Open protocol

+ Expand

Radiolabeling and Purification of [18F]6

Check if the same lab product or an alternative is used in the 5 most similar protocols

Fluorine-18, trapped on a QMA cartridge (Waters Corp, Milford, MA), was obtained from PETNET Solutions (Durham, NC). The ¹⁸F activity was eluted from the cartridge using tetraethylammonium bicarbonate (3 mg/mL) in acetonitrile and water (80/20, v/v, 1 mL). Solvents were evaporated at 100°C and the residual water was removed by azeotroping with acetonitrile (3 × 0.3 mL) at 100°C. Trimethylammonium triflate precursor 11 (0.3 mg, 0.27 μmol) in 0.15 mL anhydrous acetonitrile was added to the dried ¹⁸F activity (2.0–3.1 GBq; 53.6–83.2 mCi), and the mixture was heated at 40°C for 15 min. The crude mixture containing [¹⁸F]6 was purified using the Beckman Gold HPLC system using an XBridge C18 column eluted with 53% ethanol in sodium acetate buffer (0.05 M, pH 5.5) at a flow rate of 1.5 mL/min (t_R of [¹⁸F]6 = 16.4 min). For in vitro cell studies, [¹⁸F]6 isolated from the HPLC was added directly to the cell culture medium with the result that the ethanol concentration in the medium was <0.2%. For in vivo studies in mice, HPLC-purified [¹⁸F]6 was diluted with PBS to adjust the ethanol concentration to ≤10% before injection. For assessing the molar activity (A_m) of [¹⁸F]6, the [¹⁸F]6 peak was concentrated using an Oasis^® Light HLB cartridge (30 mg sorbent, Waters).

Zhou Z., Zalutsky M.R, & Chitneni S.K. (2021). Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation. Molecular pharmaceutics, 18(10), 3871-3881.

+ Open protocol

+ Expand

Radiolabeling of [18F]Flurpiridaz with TEMPO

Check if the same lab product or an alternative is used in the 5 most similar protocols

Example 2

[¹⁸F]-fluoride (ca. 100 GBq) was produced using a GE Medical Systems PETtrace cyclotron with a silver target via the [¹⁸O](p,n) [¹⁸F] nuclear reaction. Total target volumes of 3.2-4.8 mL were used. The radiofluoride was trapped on a Waters QMA cartridge (pre-conditioned with carbonate), and the fluoride was eluted with a solution of tetrabutylammnonium hydrogen carbonate (22 mg) in water (100 μL) and acetonitrile (400 μL). Nitrogen was used to drive the solution off the QMA cartridge to the reaction vessel. The [¹⁸F]-fluoride was dried for 9 minutes at 120° C. under a steady stream of nitrogen and vacuum. A mixture of the precursor (10.2 mg) and TEMPO (1.7 mg) in MeCN (1.7 mL) was added to the dried [¹⁸F]-fluoride and the reaction mixture was heated at 120 C for 10 minutes. The crude product was diluted with water (9.3 mL) and analysed by HPLC.

The % of [¹⁸F]Flurpiridaz in the crude product was 92% with 1% of the late eluting radiolysis product. The addition of TEMPO to the labelling reaction reduces the amount of the late eluting radiolysis product (FIG. 1). The present inventors deduce from these results that even when carried out at high activity the addition of TEMPO to the radiolabelling reaction acts to reduce the late eluting radiolysis product.

+ Open protocol

+ Expand

Radiolabeling of [18F]Fluoride via Solid-Phase Extraction

Check if the same lab product or an alternative is used in the 5 most similar protocols

The irradiated water containing the [¹⁸F]F⁻ was loaded onto a pre-conditioned QMA cartridge (Waters, Brazil) (130 mg, quaternary ammonium, carbonate form), and [¹⁸F]F⁻ was eluted off with 1 mL of K₂CO₃ (2 mg, 14 µmol)/Kryptofix 2.2.2 (K₂₂₂, 11 mg, 29 µmol) mixture in 2:8 Milli-Q water/MeCN [29 (link)]. [K⁺/K₂₂₂]/[¹⁸F]F⁻/CO₃²⁻ complex was dried by azeotropic distillation at 100 °C and nitrogen atmosphere with sequential addition of MeCN (1 mL, 3 times).

Sahylí Ortega Pijeira M., Sérgio Gonçalves Nunes P., Nascimento dos Santos S., Zhang Z., Pérez Nario A., Araujo Perini E., Miguel Turato W., Rodríguez Riera Z., Chammas R., H. Elsinga P., Lin K.S., Carvalho I, & Soares Bernardes E. (2020). Synthesis and Evaluation of [18F]FEtLos and [18F]AMBF3Los as Novel 18F-Labelled Losartan Derivatives for Molecular Imaging of Angiotensin II Type 1 Receptors. Molecules, 25(8), 1872.

+ Open protocol

+ Expand

Automated Radiosynthesis of [18F]LU14

Check if the same lab product or an alternative is used in the 5 most similar protocols

Remote-controlled radiosynthesis was performed using a Synchrom R&D EVO III automated synthesiser (Elysia-Raytest, Straubenhardt, Germany). Briefly, [¹⁸F]fluoride (4–6 GBq) was trapped on a Waters QMA cartridge and eluted with a solution containing 5.6 mg K222 and 40 μL K₂CO₃ dissolved in a mixture of H₂O/MeCN (1 mL, 1:4, v/v) into the reaction vessel and dried via azeotropic distillation. An additional 1.5 mL of dried MeCN was added. After complete dryness, a solution containing 1 mg of precursor 7 in 800 µL DMSO was added, and the reaction mixture was stirred at 150 °C for 10 min. Upon cooling to 40 °C, the reaction mixture was diluted with 4 mL H₂O, and the resulting solution was transferred to the semi-preparative HPLC. [¹⁸F]LU14 was collected in the HPLC collection vial containing 40 mL of H₂O and trapped in the Sep-Pak^® C18 light cartridge (Waters GmbH, Eschborn, Germany). The cartridge was washed with 2 mL H₂O, and [¹⁸F]LU14 was eluted with 1.2 mL EtOH. This ethanolic solution was transferred outside of the shielded cell, and the solvent was evaporated at 70 °C in a gentle stream of nitrogen for 5–10 min, and [¹⁸F]LU14 was reconstituted in isotonic saline solution for further biological characterisation. Total synthesis time was about 70 min.

Teodoro R., Gündel D., Deuther-Conrad W., Ueberham L., Toussaint M., Bormans G., Brust P, & Moldovan R.P. (2021). Development of [18F]LU14 for PET Imaging of Cannabinoid Receptor Type 2 in the Brain. International Journal of Molecular Sciences, 22(15), 8051.

+ Open protocol

+ Expand

Remote-Controlled Radiosynthesis of [18F]LUZ5-d8

Check if the same lab product or an alternative is used in the 5 most similar protocols

Remote-controlled radiosynthesis
was performed using a Synchrom R&D EVO III automated synthesizer
(Elysia-Raytest). Briefly, [¹⁸F]fluoride (5–12 GBq)
was trapped on a Waters QMA cartridge, eluted with a H₂O/CH₃CN [1 mL, 1:4 (v/v)] solution containing 2.2.2-cryptand
(K_2.2.2) (11 mg) and K₂CO₃ (75 μL)
into the reaction vessel, and dried via azeotropic distillation. To
complete the azeotropic distillation, additional dry CH₃CN (1.5 mL) was added. After complete dryness, precursor 19 (1 mg, 22.65 μmol) in CH₃CN (1 mL) was added and
the reaction mixture was stirred at 90 °C for 10 min. The reaction
mixture was diluted with 4 mL of H₂O/CH₃CN (1:1),
and the solution was transferred to the semipreparative HPLC instrument. [¹⁸F]LUZ5-d₈ was collected via the HPLC collection
vial containing 40 mL of H₂O and trapped in the Sep-Pak
C18 light cartridge. The cartridge was washed with 2 mL of H₂O, and [¹⁸F]LUZ5-d₈ was eluted with 1.3 mL
of EtOH. This ethanolic solution was transferred outside of the shielded
cell; the solvent was evaporated at 70 °C in a gentle stream
of nitrogen for 5–10 min, and [¹⁸F]LUZ5-d₈ was reconstituted in an isotonic saline solution for further biological
characterization. The total synthesis time was ∼85 min.

Ueberham L., Gündel D., Kellert M., Deuther-Conrad W., Ludwig F.A., Lönnecke P., Kazimir A., Kopka K., Brust P., Moldovan R.P, & Hey-Hawkins E. (2023). Development of the High-Affinity Carborane-Based Cannabinoid Receptor Type 2 PET Ligand [18F]LUZ5-d8. Journal of Medicinal Chemistry, 66(7), 5242-5260.

+ Open protocol

+ Expand

Automated Radiosynthesis of [18F]RM365

Check if the same lab product or an alternative is used in the 5 most similar protocols

Remote
controlled radiosynthesis was performed using a Synchrom R&D EVO
III automated synthesizer (Elysia-Raytest, Straubenhardt, Germany).
Briefly, [¹⁸F]fluoride (8–12 GBq) was trapped on
a Waters QMA cartridge and eluted with a solution containing 100 μL
of TBAHCO₃ and 30 μL of K₂CO₃ dissolved in a mixture of H₂O/MeCN (1 mL, 1:4, v/v) into the reaction vessel and dried via azeotropic distillation.
A further 1.5 mL of dried MeCN was added. After complete dryness,
a solution of 13.2 μmol of Cu(Py)₄(OTf)₂ in 450 μL of DMA/t-BuOH (2:1, v/v) was added, followed by a solution of 6.6 μmol of boronic
acid pinacol ester 24 in 450 μL of DMA/t-BuOH (2:1, v/v), and the reaction mixture
was stirred at 120 °C for 10 min. Upon cooling to 40 °C,
the reaction mixture was diluted with H₂O/MeCN (4 mL, 1:4, v/v), and the solution was transferred to the semipreparative
HPLC. [¹⁸F]RM365 was collected in the HPLC collection vial
containing 40 mL of H₂O and trapped in the Sep-Pak C18
light cartridge. The cartridge was washed with 2 mL of H₂O and [¹⁸F]RM365 eluted with 1.3 mL of EtOH. This ethanolic
solution was transferred outside of the shielded cell, the solvent
was evaporated at 70 °C in a gentle stream of nitrogen for 5–10
min, and [¹⁸F]RM365 was reconstituted in an isotonic saline
solution for further biological characterization. The total synthesis
time was about 75 min.

Teodoro R., Gündel D., Deuther-Conrad W., Kazimir A., Toussaint M., Wenzel B., Bormans G., Hey-Hawkins E., Kopka K., Brust P, & Moldovan R.P. (2023). Synthesis, Structure–Activity Relationships, Radiofluorination, and Biological Evaluation of [18F]RM365, a Novel Radioligand for Imaging the Human Cannabinoid Receptor Type 2 (CB2R) in the Brain with PET. Journal of Medicinal Chemistry, 66(20), 13991-14010.

+ Open protocol

+ Expand

Radiolabeling of Al^18F-NOTA-FAPI

Check if the same lab product or an alternative is used in the 5 most similar protocols

As shown in Fig. 1, radiolabeling of Al 18 F-NOTA-FAPI was completed based on a previous reported method with some modifications [20] . Briefly, 18 F  was produced from HM-20 medical cyclotron (Sumitomo Corporation, Japan), loaded on QMA cartridge (Waters Corporation, USA) and further eluted with saline (0.3-0.5 mL). For the radiolabeling, 18 F  in saline (0.1 mL, 555-3330 MBq) was mixed with AlCl3 (6 μL, 2 mM) and KHP (6 μL, 0.5 M) for 5 min under room temperature to form the [Al 18 F] 2+ conjugate, NOTA-FAPI precursor (5 μL, 4 mM) was further added to the reaction system and heated at 110 o C for 15 min. After that, the reaction system was diluted with 5 mL of ultrapure water and purified with Sep-Pak Light C18 cartridge (Waters Corporation, USA). Final product was formulated through the elution of C18 cartridge with 0.5 mL of 80% ethanol and 6 mL of saline consecutively, and further passed through a 0.2 μm syringe filter (Pall Corpotation, USA). The radiochemical purity of Al 18 F-NOTA-FAPI was analyzed by a radio high performance liquid chromatograph (1200 Series, Agilent, USA) with gradient elution: 0-3 min, 95% water (0.1% TFA) + 5% acetonitrile (0.1% TFA); 18 min, 5% water (0.1% TFA) + 95% acetonitrile (0.1% TFA); 20 min, 95% water (0.1% TFA) + 5% acetonitrile (0.1% TFA).

Wang S., Zhou X., Xu X., Ding J., Liu S., Hou X., Li N., Zhu H, & Yang Z. (2021). Clinical translational evaluation of Al¹⁸F-NOTA-FAPI for fibroblast activation protein-targeted tumour imaging. European journal of nuclear medicine and molecular imaging, 48(13).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!